Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine
Emerging Biological Drugs – This New Study Reveals Selling Opportunities and Revenue Prospects to Help You Stay Ahead What is the future of biologics, especially new drug classes? Now get the latest technological and commercial analysis. Staying ahead in data and knowledge, you benefit your influence. And you explore trends, developments, results, opportunities and sales predictions.
Visiongain’s new study reveals what is possible for biological drugs – their lucrative next phase. That survey helps you avoid missing out. Instead find developments in that industry and market, discovering expected progress and revenues. Discover where the money lies.
New biotechnological medicines will benefit patients and pharmaceutical companies. Read on to explore those therapies, seeing how high revenues can go.
Forecasting and other information showing the most promising opportunities for treatments Our updated report gives sales forecasts to 2026 at overall world, submarket, product and national level. You see what the future holds, assessing gains for developers and producers.
Many opportunities exist. And besides giving revenue predictions, our analysis shows you recent results, growth rates and market shares. In that report you discover 127 tables, 47 charts and four interviews with companies. See, from 2016, what is possible.
In our study you get intelligence on competitors and their activities, especially products, deals and R&D. The following sections explain what that new investigation gives you.
Analyses exclusive to that study, showing the most important commercial potentials In our report you get data found nowhere else. Discover what is happening and what is possible from 2016.
Our analysis benefits your plans, decisions and influence by interpreting medical needs, R&D and companies’ technologies. There you hear what is happening, assessing opportunities and likely gains.
With those analyses you see where potential and money lie, also saving time and effort. That way you can also benefit your reputation for technological and commercial insight. The following sections explain how our study helps your work.
Prospects for that world market and submarkets – discover what is possible for next-generation biopharmaceuticals In our report you see overall world sales to 2026 for those emerging biotherapies, exploring our discussions.
Also you gain individual revenue predictions to 2026 for six next-generation biologic submarkets at world level and their further subdivisions: • Next-generation antibody therapies, including the subsectors of antibody-drug conjugates (ADCs), engineered antibodies and bispecific treatments • Next-generation antibody fragments and antibody-like proteins (ALPs) • Next-generation insulins, including submarkets assessing oral insulins, ultra-long and ultra-rapid acting therapies • Next-generation recombinant coagulation factors • Next-generation growth hormones • Regenerative medicine, including tissue engineering, gene therapies and stem cells.
Our study also explores competition. There you see what is happening for developers, producers and sellers of new-generation biologics, understanding challenges, trends and outlooks. Explore what is possible.
That work also splits its overall world market into leading products, showing where you could profit from new and improved biotechnological medicines.
Product forecasts for new forms, variations and uses of biological therapy How will individual drugs perform to 2026 at world level? Our report predicts revenues of eight top brands: • Kadcyla • Adcetris • Tresiba • Alprolix • Eloctate • Gazyva/Gazyvaro • Plegridy • Afrezza.
There you explore products and years with highest predicted sales. You also examine competitors. Hear what is happening, understanding challenges, trends, competition and opportunities.
For treating people and saving lives, you investigate progress, needs and possibilities. Discover how pharma companies satisfy those demands, also assessing expected financial gains from 2016.
Our work also shows you geographical revenue forecasts.
Demand in national markets – what outlooks for business in new biopharma products? Advances in biotechnology and healthcare expand use of novel biological drugs in developed and developing countries. Many opportunities exist for new, improved treatments.
Our analyses show you individual revenue forecasts to 2026 for nine national markets: • United States • Japan • Germany, France, United Kingdom, Italy and Spain • China • India.
There you hear about the best sales potentials, appraising national opportunities for next-generation biologics. See where revenues can rise, finding how you could gain.
And what events influence the biological drugs industry? What is the outlook for tackling serious diseases? Our work shows you, discussing trends, challenges and opportunities.
Market forces and issues – what affects biopharma developers, producers and sellers? The report explains trends, processes and events affecting the follow-on biopharmaceuticals industry and market from 2016, including these forces: • Demands and needs for new biological therapies • Limitations of existing medicines • Promise of next-generation biologics and product launches • Extension of half-life – pegylation and other technologies • Contract manufacturers (CMOs) serving those developmental needs and trends.
And you explore these influences, among others: • Disease incidence and prevalence affecting demand for those new medicines • Improvements in therapeutic antibodies and variants, including targeted cytotoxic therapies • R&D pipelines – e.g. for immunotoxins – including agents in clinical development • Biosimilars and other follow-on protein agents transforming the biologics market • Effects of rising incidence rates in diabetes, cardiovascular disorders and cancer.
There discover what the future holds. That way you investigate political, economic, social and technological questions. And you find how R&D helps companies benefit patients.
With our study you explore what progress, trends and opportunities mean. And you discover what helps and hinders participants in the biomedical industry, affecting companies’ results.
Biological drug technology and applications – companies and 2020 market value What happens next? From 2016, novel follow-on treatments will benefit patients, healthcare providers and biomedical companies. Those advances will encourage investments, progress and higher revenues from more-advanced biological drugs. Discover what is possible.
Our study predicts the next-generation biologics market will reach $21.3bn worldwide in 2020, with strong revenue growth to 2026. See what the future holds for those products.
That work explores activities of these leading companies, among many other biopharmaceutical developers and producers: • Novo Nordisk • Eli Lilly • Bayer • Sanofi • Pfizer.
In that market large pharmaceutical corporations and smaller biopharma specialists can win. See how, exploring what is possible.
You also gain interviews with four companies – Ablynx, Crescendo Biologics, Sorrento Therapeutics and Affibody – helping you stay ahead in knowledge. Discover what is happening. See what organisations shaping that industry do, helping you succeed.
5 Ways Next-Generation Biologics Market 2016-2026 helps your analyses, plans and decisions In these five main ways our new investigation helps you gain recognition for insight, benefiting your authority: • Revenues to 2026 at world level, for 17 market segments and 8 products – explore outlooks for R&D, production, marketing and sales • Forecasts to 2026 for 9 national markets in North America, Europe and Asia – assess countries for revenues and sales growth opportunities • Prospects for established competitors, rising companies and new entrants – investigate R&D, product portfolios, results and strategies • Analysis of what stimulates and restrains that industry and market – assess challenges and strengths, helping you compete and gain advantages • Interviews with 4 companies shaping that industry – discover what authorities say and do, helping you stay ahead in knowledge and succeed.
There you gain competitive intelligence found only in our analysis, finding sales potentials. Benefit your influence by exploring commercial progress, opportunities and prospects.
Trying our study now lets you discover biological drug trends, opportunities and forecasts With our new report, by Visiongain’s UK-based in-house analysts, you discover analysis to help you stay ahead in knowledge. See there what the future holds for developers, producers and sellers of next-generation biomedicines. Find data you get nowhere else.
Our investigation is for everyone analysing biopharmaceuticals. There you discover data and forecasts for next-phase biopharmaceuticals. Avoid missing out and falling behind in knowledge. Instead please get our new report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 Overview of the Next-Generation Biologics Market
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Reports
1.9 About Visiongain
2. Introduction to Next-Generation Biologics
2.1 Brief History of Biological Drug Development
2.1.1 Limitations of Present-Generation Biological Drugs
2.2 The Promise of Next-Generation Biologics
2.2.1 Defining Next-Generation Biologics
2.2.1.1 A Definition of Regenerative Medicine
2.2.1.2 Extending Half-Life: Pegylation and Other Novel Strategies
3. World Next-Generation Biologics Market: Outlook and Forecast 2016-2026
3.1 The Next-Generation Biologics Market 2015
3.1.1 Development of the Next-Generation Biologics Market 2008-2015
3.1.2 Rising Demand for Biological Therapies
3.1.3 Next-Generation Drugs as a Share of the Biologics Market 2015
3.1.4 Main Sectors of the Next-Generation Biologics Market: Antibodies and Regenerative Medicine Lead the Way
3.1.5 Leading Companies in the Next-Generation Biologics Market 2015
3.2 The Next-Generation Biologics Market 2016-2026
3.2.1 Growth Drivers for Biological Drug Revenues 2016-2026
3.2.2 The Next-Generation Biologics Market Forecast 2016-2026
3.2.3 Product Launches in All Sectors to Drive Market Growth 2016-2026
10.3 The Next-Generation Biologics Market: STEP Analysis 2016-2026
10.3.1 Social Factors: Rising Disease Incidence and Demands for Convenience
10.3.1.1 Rising Incidence in Cardiovascular Disease, Cancer and Diabetes
10.3.1.2 Next-Generation Biologic Development in Emerging Markets
10.3.2 Technological Developments 2016-2026
10.3.3 Economic Pressures 2016-2026
10.3.3.1 High Drug Costs and Healthcare Spending
10.3.3.2 Limited Commercial Potential in Emerging Markets?
10.3.4 Political Issues: Regulatory Developments 2016-2026
10.4 Next-Generation Biologics: Development Trends 2016-2026
10.4.1 Improving Patient Convenience
10.4.2 Sustained Release Biologics: Pegylation and Beyond
10.4.3 Therapeutic Focus for Next-Generation Biologics
10.4.4 Next-Generation Biologics as Personalised Medicine
10.5 Manufacturing Challenges and Opportunities for Next-Generation Biologics
10.5.1 Contract Manufacturers Invest to Follow Development Trends
10.6 Commercialising Next-Generation Biologics
10.6.1 Product Lifecycle Management for First Generation Biologics
10.6.2 Proving Benefit in Next-Generation Products
10.6.3 Biosimilars as a Challenger 2016-2026
10.7 Partnering for Next-Generation Biologic Development
10.7.1 The Role of Big Pharma in the Next-Generation Biologics Market
10.7.2 Most Development Platforms Stem from Small Biotechs
11. Research Interviews from Our Survey
11.1 Dr Edwin Moses, CEO, Ablynx
11.1.1 Ablynx
11.1.2 Ablynx’s Pipeline and Nanobody Technology
11.1.3 On Caplacizumab
11.1.4 Challenged with Current Biological Therapies
11.1.5 The Next-Generation Biologics Market, 2016-2026
11.2 Dr Mike Romanos, CEO, Crescendo Biologics
11.2.1 Crescendo Biologics
11.2.2 The Benefits in Antibody Fragment Therapies
11.2.3 Treatment of Inflammation Indications with Antibody Fragments
11.2.4 Crescendo’s Fragment Pipeline
11.2.5 Development and Production Platforms for Antibody Therapies
11.2.6 Crescendo’s Humabody ADCs and Multi-Specific T-Cell Engagers
11.2.7 CB001, A Topical Biologic
11.2.8 The Next-Generation Biologics Market, 2015-2025
11.3 Sorrento Therapeutics Inc. Team: Dr Gunnar Kaufmann, VP of Research; Dr Kouros Motamed, VP, Strategic Alliances and Clinical Communications; George Uy, EVP and CCO
11.3.1 Sorrento Therapeutics Inc.
11.3.2 Sorrento’s Pipeline
11.3.3 Drivers and Restraints for Next-Generation Biologics
11.3.4 The Next-Generation Biologics Market, 2015-2025
11.4 Dr Fredrik Frejd, CSO, Affibody
11.4.1 Affibody
11.4.2 Challenges with Current Biological Therapies
11.4.2.1 Current Half-Life Extension Technologies
11.4.3 The Benefits of Affibodies Over Current Antibody Therapies
11.4.4 Focus on Inflammation and Autoimmune Diseases
11.4.5 Development of SOBI002
11.4.6 Regulatory Challenges with Novel Biologics
12. Conclusions from Our Research and Analysis
12.1 The Next-Generation Biologics Market Will Grow Strongly to 2026
12.2 Next-Generation Antibody Development Will Lead the Market
12.3 New Treatment Regimens Will Drive Demand for Next-Generation Biologics
12.4 Leading Regional Markets
12.5 Challenges Remain in Developing and Commercialising Next-Generation Biologics
List of Tables
Table 2.1 First Approvals for Recombinant Protein Therapies, 1982-1997
Table 3.1 Top Ten Bestselling Prescription Pharmaceuticals: Revenues ($bn), 2015
Table 3.2 Next-Generation Biologics Market: Revenues by Sector ($bn), 2015
Table 3.3 Biological Drugs Market: Drivers and Restraints, 2016-2026
Table 3.4 Next-Generation Biologics Market: Overall Market Forecast and Revenue Forecasts ($bn) by Sector, 2015-2020
Table 3.5 Next-Generation Biologics Market: Overall Market Forecast and Revenue Forecasts ($bn) by Sector, 2021-2026
Table 3.6 Next-Generation Biologics: Market Shares (%) by Sector, 2015, 2020 and 2026
Table 4.1 Next-Generation Biologics Market: Revenues ($bn) by National Submarket, 2015
Table 4.2 Next-Generation Biologics Market: Revenues ($bn) by National Submarket, 2015-2020
Table 4.3 Next-Generation Biologics Market: Revenues ($bn) by National Submarket, 2021-2026, Part 1
Table 4.4 Next-Generation Biologics Market: Revenues ($bn) by National Submarket, 2021-2026, Part 2
Table 4.5 Next-Generation Biologics: Market Shares (%) by National Submarket, 2020 and 2026
Table 4.6 National Incidence and Prevalence of Leading Indications Treated with Biologics (millions of patients), 2015
Table 4.7 Main Approval Dates for Next-Generation Biologics in Leading National Submarkets, 2003-2013
Table 4.8 US Next-Generation Biologics Submarket Forecast ($bn), 2015-2020
Table 4.9 US Next-Generation Biologics Submarket Forecast ($bn), 2021-2026
Table 4.10 Biosimilars Approved and Marketed in Japan, 2015
Table 4.11 Japanese Next-Generation Biologics Submarket Forecast ($bn), 2015-2020
Table 4.12 Japanese Next-Generation Biologics Submarket Forecast ($bn), 2021-2026
Table 4.13 Next-Generation Biologics Submarkets in the EU5 Nations: Revenues ($bn), 2015
Table 4.14 German Next-Generation Biologics Submarket Forecast ($bn), 2015-2020
Table 4.15 German Next-Generation Biologics Submarket Forecast ($bn), 2021-2026
Table 4.16 French Next-Generation Biologics Submarket Forecast ($bn), 2015-2020
Table 4.17 French Next-Generation Biologics Submarket Forecast ($bn), 2021-2026
Table 4.18 UK Next-Generation Biologics Submarket Forecast ($bn), 2015-2020
Table 4.19 UK Next-Generation Biologics Submarket Forecast ($bn), 2021-2026
Table 4.20 Italian Next-Generation Biologics Submarket Forecast ($bn), 2015-2020
Table 4.21 Italian Next-Generation Biologics Submarket Forecast ($bn), 2021-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
